PNC-27

Originally developed as a targeted cancer therapy, this synthetic peptide was designed to distinguish between malignant and healthy tissue at the cellular level. Cancer research laboratories have investigated PNC-27 as a potential treatment that could theoretically destroy tumor cells without the widespread cellular damage associated with conventional chemotherapy. The peptide represents an attempt to create more precise cancer interventions, though clinical applications remain distant.

PNC-27 works by binding to a protein called HDM-2, which is often overproduced in cancer cells but less abundant in normal cells. When the peptide attaches to HDM-2, it forms a complex that punches holes in the cell membrane, causing the cell to die. The selective toxicity occurs because healthy cells typically don't have enough HDM-2 for the peptide to latch onto effectively, leaving them largely unharmed.